CryoCell Short Long Term Debt vs Current Deferred Revenue Analysis
| CCEL Stock | USD 9.00 0.13 1.47% |
CryoCell International financial indicator trend analysis is way more than just evaluating CryoCell International prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether CryoCell International is a good investment. Please check the relationship between CryoCell International Short Long Term Debt and its Current Deferred Revenue accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CryoCell International. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. For more information on how to buy CryoCell Stock please use our How to buy in CryoCell Stock guide.
Short Long Term Debt vs Current Deferred Revenue
Short Long Term Debt vs Current Deferred Revenue Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of CryoCell International Short Long Term Debt account and Current Deferred Revenue. At this time, the significance of the direction appears to have fragmental relationship.
The correlation between CryoCell International's Short Long Term Debt and Current Deferred Revenue is 0.52. Overlapping area represents the amount of variation of Short Long Term Debt that can explain the historical movement of Current Deferred Revenue in the same time period over historical financial statements of CryoCell International, assuming nothing else is changed. The correlation between historical values of CryoCell International's Short Long Term Debt and Current Deferred Revenue is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Short Long Term Debt of CryoCell International are associated (or correlated) with its Current Deferred Revenue. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Current Deferred Revenue has no effect on the direction of Short Long Term Debt i.e., CryoCell International's Short Long Term Debt and Current Deferred Revenue go up and down completely randomly.
Correlation Coefficient | 0.52 |
| Relationship Direction | Positive |
| Relationship Strength | Weak |
Short Long Term Debt
The total of a company's short-term and long-term borrowings.Current Deferred Revenue
Revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends.Most indicators from CryoCell International's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into CryoCell International current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CryoCell International. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. For more information on how to buy CryoCell Stock please use our How to buy in CryoCell Stock guide.The value of Selling General Administrative is expected to slide to about 11.2 M. Tax Provision is expected to rise to about (3.3 M) this year
| 2021 | 2022 | 2023 | 2024 (projected) | Gross Profit | 21.5M | 22.9M | 26.3M | 27.7M | Total Revenue | 30.3M | 31.3M | 36.0M | 18.4M |
CryoCell International fundamental ratios Correlations
Click cells to compare fundamentals
CryoCell International Account Relationship Matchups
High Positive Relationship
High Negative Relationship
CryoCell International fundamental ratios Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 46.2M | 60.7M | 64.9M | 61.2M | 70.4M | 73.9M | |
| Other Current Liab | 1.9M | 8.0M | 5.2M | 4.9M | 5.7M | 6.0M | |
| Total Current Liabilities | 16.4M | 21.1M | 19.5M | 20.9M | 24.0M | 25.2M | |
| Total Stockholder Equity | (2.7M) | 4.2M | (1.5M) | (11.0M) | (9.9M) | (9.4M) | |
| Property Plant And Equipment Net | 1.9M | 4.1M | 14.2M | 22.0M | 25.3M | 26.6M | |
| Net Debt | (4.1M) | (5.4M) | 9.9M | 10.5M | 9.4M | 9.0M | |
| Retained Earnings | (18.8M) | (16.7M) | (21.6M) | (31.2M) | (28.0M) | (29.4M) | |
| Accounts Payable | 957.4K | 1.5M | 1.6M | 3.2M | 3.7M | 3.8M | |
| Cash | 10.4M | 8.3M | 1.7M | 406.1K | 467.0K | 443.6K | |
| Non Current Assets Total | 27.6M | 44.9M | 55.3M | 51.8M | 59.5M | 62.5M | |
| Non Currrent Assets Other | 11.6M | 10.3M | 9.9M | 6.3M | 7.3M | 7.6M | |
| Cash And Short Term Investments | 10.4M | 8.3M | 1.7M | 980.3K | 1.1M | 1.1M | |
| Net Receivables | 6.3M | 5.3M | 6.0M | 6.6M | 7.6M | 7.9M | |
| Common Stock Shares Outstanding | 8.1M | 8.4M | 8.5M | 8.3M | 7.5M | 7.8M | |
| Liabilities And Stockholders Equity | 46.2M | 60.7M | 64.9M | 61.2M | 70.4M | 73.9M | |
| Non Current Liabilities Total | 32.5M | 35.4M | 46.9M | 51.4M | 59.1M | 62.1M | |
| Other Stockholder Equity | 16.0M | 20.8M | 20.0M | 20.0M | 23.0M | 21.5M | |
| Total Liab | 48.9M | 56.5M | 66.4M | 72.3M | 83.1M | 87.2M | |
| Total Current Assets | 18.6M | 15.8M | 9.6M | 9.5M | 10.9M | 10.5M | |
| Intangible Assets | 1.5M | 16.2M | 15.2M | 989.1K | 1.1M | 2.0M | |
| Short Long Term Debt Total | 6.2M | 2.8M | 11.6M | 10.9M | 9.8M | 9.3M | |
| Other Current Assets | 856.3K | 1.3M | 993.4K | 1.1M | 1.3M | 871.7K | |
| Short Term Debt | 3.4M | 2.2M | 2.7M | 1.6M | 1.9M | 1.6M | |
| Short Term Investments | 88.5K | 75.4K | 17.6K | 574.2K | 516.8K | 641.7K | |
| Common Stock | 136.3K | 146.7K | 148.5K | 148.5K | 170.8K | 134.7K | |
| Other Liab | 28.6M | 29.6M | 34.8M | 38.0M | 43.7M | 45.9M | |
| Other Assets | 22.2M | 21.9M | 22.3M | 23.7M | 27.2M | 28.6M | |
| Long Term Debt | 5.9M | 2.8M | 8.6M | 8.4M | 9.7M | 5.2M | |
| Property Plant Equipment | 1.8M | 1.6M | 4.1M | 14.2M | 16.3M | 17.2M | |
| Current Deferred Revenue | 9.2M | 9.4M | 9.6M | 9.7M | 11.2M | 6.4M | |
| Net Tangible Assets | (10.1M) | (2.7M) | (14.0M) | (18.6M) | (16.8M) | (17.6M) | |
| Non Current Liabilities Other | 32.5M | 3.5M | 2.0M | 919.2K | 827.3K | 785.9K | |
| Inventory | 927.3K | 921.2K | 851.2K | 768.9K | 692.0K | 657.4K |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Trending Equities to better understand how to build diversified portfolios, which includes a position in CryoCell International. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. For more information on how to buy CryoCell Stock please use our How to buy in CryoCell Stock guide.You can also try the Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.
Is Health Care Providers & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CryoCell International. If investors know CryoCell will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CryoCell International listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.625 | Earnings Share (1.07) | Revenue Per Share 3.89 | Quarterly Revenue Growth 0.025 | Return On Assets (0) |
The market value of CryoCell International is measured differently than its book value, which is the value of CryoCell that is recorded on the company's balance sheet. Investors also form their own opinion of CryoCell International's value that differs from its market value or its book value, called intrinsic value, which is CryoCell International's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CryoCell International's market value can be influenced by many factors that don't directly affect CryoCell International's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CryoCell International's value and its price as these two are different measures arrived at by different means. Investors typically determine if CryoCell International is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CryoCell International's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.